Navigation Links
OriGene Technologies and EdiGene Announce Joint Development of Genome Wide Knockout Cell Lysates, Revolutionizing Western Blot and Antibody Specificity Validation
Date:11/22/2016

OriGene Technologies, the industry’s largest supplier of gene-centric research tools, today announced that it has entered into a multi-year strategic agreement with EdiGene (Beijing, China) to develop genome wide knockout cells from commonly used laboratory cell lines. This joint adventure combines EdiGene’s technical expertise in genome editing technology and OriGene’s extensive market reach to serve the research community.

Performance and specificity are critical for antibodies to be used effectively in research, diagnostic and therapeutic applications, yet reagents to validate antibody specificity are currently lacking. The Knockout Cell Lysates from OriGene are specifically designed to drastically improve the process by which antibody performance is verified and target specificity is confirmed by scientists.

With its high capacity technology platform, EdiGene has started large-scale production of the industry’s first attempt to create a genome-wide gene knockout cell library. The first product line that OriGene has introduced is the Knockout Cell Lysate, a new category of protein products, which can be used to validate antibodies for specificity or used as high quality negative controls for Western blot analysis.

Introduction of the Knockout Cell Lysates follows OriGene’s previous announcement to develop and deliver to the industry leading technology solutions such as its 10K High Density Protein Microarray Platform and UltraMAB™ Antibodies featuring extensive validation, “mono-specificity” characteristics and guaranteed no cross-reactivity as determined by protein microarray technology for use in IHC applications and immunoassays.

KO Cell Lysate Overview:

Derived mostly from HEK293T and HeLa cell lines, EdiGene KO Cell lysates have been optimized through the use of genome editing technology and validated at the genomic level through PCR and Sanger sequence techniques to ensure the accuracy and knockout of the target gene. Each KO Cell Lysate product is sold in kit format consisting of a KO Cell lysate and a Parental cell lysate, which are immediately available from OriGene to the academic and industrial research markets.

“The introduction of novel tools such as the Ready-Made Knockout Cell Lysates has the potential and power to completely revolutionize Western blotting and improve the current state of product quality for the wider Antibody Industry. OriGene’s continued pursuit of best in class technologies for improved antibody validation and specificity determination further underscores our long-term commitment to becoming a leading producer of antibody products. Through our unique relationship with leading companies like EdiGene, we now have the ability to transform biological research through the delivery of Knockout Cell Lysates and use of leading technologies such as CRISPR” stated Dr. Wei-Wu He, CEO, OriGene Technologies.

In a related statement, Dr. Wensheng Wei (CSO & Founder, EdiGene) commented “We are excited about the collaboration between EdiGene and OriGene that combines the high-quality KO cell line products from EdiGene as a leading Genome Editing company in China and the worldwide distribution channel of OriGene as one of the leading reagent companies. The adaptation of KO validation in the antibody reagent industry and the scientific research community will redefine antibody quality and improve the accuracy and reproducibility of experimental results using antibodies.”

Additional information about the KO Cell Lysates from OriGene is available at http://www.origene.com/Protein/KO-Lysate/

About OriGene Technologies
OriGene Technologies, Inc. is a gene centric life sciences company dedicated to support academic, diagnostic, pharmaceutical and biotech companies in their research of gene functions and drug discovery. OriGene's novel product line includes the world's largest cDNA and shRNA clone collections, ready-to-use Lenti particles, over 12,000 purified human proteins produced from mammalian (HEK293) cells, over 50,000 high quality primary antibodies including TrueMAB™ mouse monoclonal antibodies and polyclonal antibodies made against full-length proteins for the conservation of native epitopes, validated “mono-specific” monoclonal antibodies called UltraMAB®, which offer a unique solution to the critical issue of antibody specificity, >140,000 highly validated human tissues, and protein microarray products and services. For more information, visit http://www.origene.com.

About EdiGene Inc.
EdiGene Corporation is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. We aim at providing high quality products and services for patients, pharmaceutical industry, diagnostic industry and scientific research community. EdiGene produces stable genome edited mammalian cell lines serving a wide-range of R&D activities in areas of basic research, diagnostic and therapeutic development. EdiGene’s Ready-Made KO Cells are utilized as Reference Standards in antibody KO validation for high quality antibody QC, as well as in diagnostic products. EdiGene provides Custom Genome Editing Service and CRISPR/Cas9 based High Throughput Genetic Screening Service to identify genes related to drug-sensitivity, drug-resistance, and synthetic lethality, and to accelerate drug discovery and clinical trials. For more information, visit http://www.edigene.com.

Read the full story at http://www.prweb.com/releases/2016/11/prweb13874007.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related medicine news :

1. SDIX, LLC, an OriGene Company, Achieves Significant Milestone with ISO 13485:2003 Certification
2. OriGene Technologies Strengthens Antibody Portfolio by Acquiring Acris Antibodies GmbH
3. OriGene Technologies Awarded Phase II SBIR Contract to Develop High-Affinity, Anti-Peptide Monoclonal Antibodies for SISCAPA Assays
4. OriGene & Dako Establish Multi-year Antibody Development Collaboration and Announce Commercial License Grant for “Ultra-Specific” Monoclonal Antibody for ALK Detection
5. OriGene's ALK UltraMAB® Antibody (OTI1A4) Outperform D5F3 Antibody, Successfully Demonstrating Higher Sensitivity in NSCLC Immunohistochemistry Diagnostics
6. New Interactive Web Tool Helps Innovators Match Formulations to Drug Delivery Technologies
7. Global Forensic Technologies Market is Expected to Reach USD 17.7 Billion in 2019: Transparency Market Research
8. BCC Research Publishes A New Report on Global Markets for Biorefinery technologies
9. Lawful Interception Market (Components, Technologies, Interface) Worth $970.6 Million by 2018 - New Report by MarketsandMarkets
10. State Fire Marshal Advises Those Using New Communication Technologies to Test Their Alarm Monitoring Systems
11. Cycle Technologies Announces Newly Optimized Mobile Website This Fall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/19/2020)... ATLANTA (PRWEB) , ... March 19, 2020 , ... ... training curriculum designed to teach Executive Function, shares a free Student Learning Exercise: ... to COVID-19, many parents and teachers are seeking resources to help with the ...
(Date:3/19/2020)... ... ... “We wanted to solve the challenges of safely getting testing for COVID-19 in ... reliable at home testing kit that can be processed quickly allows us to give ... their own home, while maintaining the health of the general public." , Members can ...
(Date:3/16/2020)... ... March 16, 2020 , ... To avoid ... Delta Human Services Authority is implementing several new universal health and safety measures ... clients and staff," said Dr. Monteic A. Sizer, executive director of Northeast Delta. ...
(Date:3/15/2020)... ... March 13, 2020 , ... ... are approximately 700,000 people with autism in the world, using a conservative rate ... have access to a life-changing intervention known as Applied Behavioral Analysis. ABA is ...
(Date:3/13/2020)... ... March 13, 2020 , ... The Berman Law Group today ... of China, Hubei Province, the City of Wuhan, and several Chinese government ministries, on ... The lawsuit was filed in the Southern District of Florida, and seeks billions of ...
Breaking Medicine News(10 mins):
(Date:3/20/2020)... BELTSVILLE, Md. (PRWEB) , ... March 20, 2020 , ... ... the previous 15 days to build a crowd-sourced database of detailed location information, such ... accurate view of a potential interaction or exposure to the virus. The app will ...
(Date:3/19/2020)... ... 19, 2020 , ... Combining multiple food allergies into a ... according to research scheduled for presentation at the 2020 American Academy of Allergy, ... situation with coronavirus disease 2019 (COVID-19). , A retrospective review was used ...
(Date:3/16/2020)... ... March 16, 2020 , ... ... patient education platform, with content available from numerous organizations. Docola enables healthcare ... they support patients before, after, or between face-to-face visits or on telemedicine ...
Breaking Medicine Technology: